Skip to main content
Advanced Technical IVT

Pulmonary Alveolar Proteinosis

Also written as: PAP — Pulmonary Alveolar Proteinosis

A rare lung disorder characterised by the accumulation of surfactant-derived lipoproteinaceous material within alveoli, impairing gas exchange.

Full Definition

Pulmonary alveolar proteinosis (PAP) in children may be congenital, autoimmune, or secondary to infection or immunodeficiency. The alveoli fill with a periodic acid–Schiff (PAS)-positive proteinaceous material that results from impaired surfactant clearance by alveolar macrophages. Congenital PAP is associated with mutations in surfactant protein genes (SP-B, SP-C) or the GM-CSF receptor. Editors should note that this condition is distinct from surfactant deficiency disorders; in PAP, surfactant is overproduced or under-cleared rather than absent. The standard treatment in older children is whole-lung lavage.

Usage

Usage note: Expand acronym PAP on first use; distinguish clearly from pulmonary arterial pressure (also PAP) in manuscripts covering cardiopulmonary topics.

In Context

  • "The radiologist's report described bilateral ground-glass opacities with 'crazy-paving' pattern, prompting further workup that confirmed pulmonary alveolar proteinosis." — Radiology report
  • "Authors must not conflate pulmonary alveolar proteinosis with surfactant deficiency, as the underlying pathophysiology and treatment differ substantially." — Manuscript review note

Also known as

PAP alveolar lipoproteinosis

Don't confuse with

surfactant deficiency pulmonary interstitial glycogenosis

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON